PMID- 34736367
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220808
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Print)
IS  - 0284-186X (Linking)
VI  - 61
IP  - 1
DP  - 2022 Jan
TI  - Analysis by region of outcomes for patients with advanced renal cell carcinoma 
      treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
PG  - 52-57
LID - 10.1080/0284186X.2021.1995041 [doi]
AB  - INTRODUCTION: METEOR was a phase 3 trial (NCT01865747) of cabozantinib versus 
      everolimus in adults with advanced or metastatic clear cell RCC previously 
      treated with VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs). This post 
      hoc analysis of METEOR compared outcomes for patients recruited from European and 
      non-European countries. MATERIAL AND METHODS: Adults with advanced/metastatic 
      clear cell RCC who had received >/= 1 prior VEGFR-TKI treatment were randomized 1:1 
      to receive cabozantinib or everolimus. Patients were categorized by recruitment 
      region: Europe or outside of Europe (rest of world [RoW]). Progression-free 
      survival (PFS), overall survival (OS), objective response rate (ORR), and adverse 
      events (AEs) were compared between regional subgroups. RESULTS: In total, there 
      were 320 eligible patients from Europe (cabozantinib, 167; everolimus, 153) and 
      338 from RoW (North America, 240 patients; Asia-Pacific, 86; Latin America, 12; 
      randomized as cabozantinib, 163; everolimus, 175). PFS and OS were longer with 
      cabozantinib than with everolimus and similar for the Europe and RoW subgroups. 
      For PFS, the hazard ratio (HR) for cabozantinib versus everolimus was 0.54 for 
      the Europe subgroup (p < .001) and 0.50 for the RoW subgroup (p < .001). For OS, 
      the HR was 0.75 for the Europe subgroup (p = .034) and 0.69 for the RoW subgroup 
      (p = .006). ORR in the Europe subgroup was 15% for cabozantinib and 3.9% for 
      everolimus (p < .001). For the RoW subgroup, ORR was 20% for cabozantinib and 
      2.9% for everolimus (p < .001). Incidence of grade 3/4 AEs were similar for the 
      Europe (cabozantinib, 74%; everolimus, 58%) and RoW subgroups (cabozantinib, 69%; 
      everolimus, 64%). CONCLUSION: In the METEOR trial, efficacy outcomes for patients 
      recruited from European and non-European countries favored cabozantinib over 
      everolimus. The efficacy and safety results for the regional subgroups were 
      consistent with those of the overall METEOR population.
FAU - Schmidinger, Manuela
AU  - Schmidinger M
AD  - Department of Urology, Medical University of Vienna, Vienna, Austria.
FAU - Motzer, Robert J
AU  - Motzer RJ
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Rolland, Frederic
AU  - Rolland F
AD  - Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
FAU - Staehler, Michael
AU  - Staehler M
AD  - Department of Urology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
FAU - Rink, Michael
AU  - Rink M
AD  - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Retz, Margitta
AU  - Retz M
AD  - Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
FAU - Csoszi, Tibor
AU  - Csoszi T
AD  - Jasz-Nagykun-Szolnok County Hospital, Szolnok, Hungary.
FAU - McCaffrey, John A
AU  - McCaffrey JA
AD  - Cancer Trials Ireland, Dublin, Ireland.
FAU - De Giorgi, Ugo
AU  - De Giorgi U
AD  - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, 
      Italy.
FAU - Caserta, Claudia
AU  - Caserta C
AD  - Medical and Translational Oncology Unit, Azienda Ospedaliera Santa Maria, Terni, 
      Italy.
FAU - Duran, Ignacio
AU  - Duran I
AD  - Medical Oncology Department, Hospital Universitario Marques de Valdecilla 
      (IDIVAL), Santander, Spain.
FAU - Benzaghou, Fawzi
AU  - Benzaghou F
AD  - Ipsen Bioscience, Oncology R&D, Cambridge, MA, USA.
FAU - Clary, Douglas O
AU  - Clary DO
AD  - Exelixis Inc., Alameda, CA, USA.
FAU - Albiges, Laurence
AU  - Albiges L
AD  - Medical Oncology, Gustave Roussy, Universite Paris-Saclay, Villejuif, France.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Tannir, Nizar M
AU  - Tannir NM
AD  - MD Anderson Cancer Center Hospital, The University of Texas, Houston, TX, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20211104
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Anilides/adverse effects
MH  - *Antineoplastic Agents/adverse effects
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Everolimus/adverse effects
MH  - Humans
MH  - *Kidney Neoplasms/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Pyridines
PMC - PMC9357268
MID - NIHMS1825572
OTO - NOTNLM
OT  - *Cabozantinib
OT  - *METEOR regional sub-analysis
OT  - *everolimus
OT  - *renal cell carcinoma
COIS- Disclosure statement No potential conflict of interest was reported by the 
      author(s).
EDAT- 2021/11/06 06:00
MHDA- 2022/01/22 06:00
PMCR- 2022/08/07
CRDT- 2021/11/05 05:28
PHST- 2021/11/06 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
PHST- 2021/11/05 05:28 [entrez]
PHST- 2022/08/07 00:00 [pmc-release]
AID - 10.1080/0284186X.2021.1995041 [doi]
PST - ppublish
SO  - Acta Oncol. 2022 Jan;61(1):52-57. doi: 10.1080/0284186X.2021.1995041. Epub 2021 
      Nov 4.